Catalyst
Slingshot members are tracking this event:
Novartis's (NVO) Midostaurin (PKC412) Granted Priority Review by FDA for Acute Myeloid Leukemia (AML) and Mastocytosis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 14, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pkc412, Priority Review, Fda, Acute Myeloid Leukemia, Advanced Systemic Mastocytosis, Sm, Midostaurin
